市場調査レポート

商品コード

1593530

ヒトマイクロバイオームの世界市場規模、シェア、成長分析：製品別、疾患別、タイプ別、エンドユーザー別、地域別 - 産業予測（2024年～2031年）

Human Microbiome Market Size, Share, Growth Analysis, By Product (Drugs, Probiotics), By Disease (Infectious Dieases, Gastrointestinal Diseases), By Type, By End User, By Region - Industry Forecast 2024-2031

出版日: 2024年11月15日
発行: SkyQuest
ページ情報: 英文 201 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のヒトマイクロバイオームの市場規模は、2022年に8億米ドルと評価され、2023年の10億1,000万米ドルから2031年には97億米ドルに成長し、予測期間（2024年～2031年）のCAGRは31.80%で成長する見通しです。

ヒトマイクロバイオームは、特に呼吸器と免疫の健康に大きく関係していることから、極めて重要な研究分野として浮上しています。研究では、腸内細菌叢の構成、特に放線菌、ファーミキューテス、バクテロイデテスの集団と呼吸器の問題との間に相関関係があることが示されており、全体的な免疫におけるマイクロバイオームの健康における重要な役割が浮き彫りになっています。例えば、SARS-CoV-2のような新興病原体に対する免疫反応を強化するために、マイクロバイオーム療法の進歩が始まっています。さらに、パンデミックは微生物診断と化学を取り巻く意識を高め、マイクロバイオータの研究と応用のための強固な市場を形成しています。国際糖尿病学会によれば、2045年までに20～79歳の6,900万人が糖尿病に罹患するという予測もあり、この動向はパンデミック後の状況においても続くものと思われます。さらに、ヒトマイクロバイオーム市場は、栄養補助食品や皮膚科治療など、多様な健康用途における微生物叢の利用拡大によって推進されています。技術革新、特に次世代シーケンシングと高度な微生物特性評価法が、この分野の成長をさらに促進しています。全体として、健康意識、人口動態の変化、技術の進歩の交差は、ヒトマイクロバイオーム市場の大幅な拡大の可能性を強調しています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Seres Therapeutics, Inc.（US）
Ferring Pharmaceuticals（Switzerland）
Biomebank（Australia）
Nestle S.A.（Switzerland）
Sanofi（France）
Seed Health, Inc.（US）
Enterome（France）
Pendulum（US）
Quantbiome, Inc.（Dba Ombre）（US）
Vedanta Biosciences, Inc.（US）
Maat Pharma SA（France）
International Flavors & Fragrances, Inc.（US）
Optibiotx Health Plc（UK）
Synlogic, Inc.（US）
Guangzhou Zhiyi Biotechnology Co., Ltd.（China）
Aobiome（US）
Siolta Therapeutics（US）
Alveolus Bio, Inc.（US）
MRM Health NV（Belgium）
Biome Inc（US）
Sanzyme Biologics（India）
Biomx（Israel）
Nubiyota（US）
Quorum Innovations（US）

Product Code: SQMIG35H2299

Global Human Microbiome Market size was valued at USD 0.8 Billion in 2022 and is poised to grow from USD 1.01 Billion in 2023 to USD 9.7 Billion by 2031, growing at a CAGR of 31.80% during the forecast period (2024-2031).

The human microbiome has emerged as a pivotal area of research, particularly due to its significant connections to respiratory and immune health. Studies have shown a correlation between gut microbiota composition-specifically populations of actinobacteria, firmicutes, and bacteroidetes-and respiratory issues, highlighting the critical role of microbiome health in overall immunity. For instance, advancements in microbiome therapies have been initiated to bolster immune response against emerging pathogens like SARS-CoV-2. Additionally, the pandemic has heightened awareness surrounding microbial diagnostics and chemistry, creating a robust market for microbiota research and applications. This trend is poised to continue in the post-pandemic landscape, fueled by an increasing prevalence of lifestyle-related diseases and an aging population, with projections estimating 69 million individuals aged 20-79 will have diabetes by 2045, according to the International Diabetes Association. Moreover, the human microbiome market is being propelled by the growing utilization of microbiota in diverse health applications, including dietary supplements and dermatological treatments. Technological innovations, particularly next-generation sequencing and advanced microbial characterization methods, are further facilitating growth within this sector. Overall, the intersection of health awareness, demographic shifts, and technological advancements underscores the potential for significant expansion in the human microbiome market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Microbiome Market Segmental Analysis

Global Human Microbiome Market is segmented by Product, Disease, Type, End User, and region. Based on Product, the market is segmented into Drugs, Probiotics, Prebiotics, and Synbiotics. Based on Disease, the market is segmented into Infectious Dieases, Gastrointestinal Diseases, Endocrine and Metabolic Disorders, and Other Diseases. Based on Type, the market is segmented into Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT), Live Biotherapeutic Product, and Others. Based on End User, the market is segmented into Hospitals and Clinics, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Human Microbiome Market

The rising incidence of chronic diseases, including gastrointestinal disorders, obesity, and diabetes, significantly propels the Global Human Microbiome market. As scientific research increasingly elucidates the relationship between gut microbiota and these health issues, there is a burgeoning demand for microbiome-based treatments and interventions. This trend is fueling interest among both healthcare professionals and patients, resulting in heightened investments in research and development, as well as the commercialization of microbiome-related products. Consequently, this market is experiencing robust growth, as stakeholders recognize the potential of microbiome-targeted therapies to address pressing health challenges and improve patient outcomes.

Restraints in the Global Human Microbiome Market

A significant restraint in the Global Human Microbiome market is the exorbitant costs associated with research and development. The intricate nature of studying microbial communities and effectively translating these insights into viable therapies necessitates substantial financial and technical resources. Furthermore, the lengthy process of clinical trials, coupled with stringent regulatory approvals, adds layers of expense and complexity, which can hinder innovation and timely market entry of new products. As companies grapple with these financial constraints, the pace of advancements within the human microbiome sector may be slowed, limiting the potential growth and evolution of therapies aimed at leveraging this complex ecosystem.

Market Trends of the Global Human Microbiome Market

The Global Human Microbiome Market is witnessing a significant trend towards personalized medicine, driven by advancements in understanding the intricate relationship between microbial composition and individual health. As researchers and pharmaceutical companies increasingly focus on tailoring therapeutic interventions to specific microbial profiles, this approach results in more precise treatments and diagnostics for microbiota-related conditions. Not only does this trend enhance the efficacy of therapeutic agents, but it also fosters the development of innovative strategies to address diverse health issues. Consequently, the market is poised for growth as personalized microbiome-based solutions become integral to modern healthcare practices.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Technology Analysis
Patent Analysis
Regulatory Landscape

Human Microbiome Market by Product

Market Overview
Drugs
Probiotics
Prebiotics
Synbiotics

Human Microbiome Market by Disease

Market Overview
Infectious Diseases
Gastrointestinal Diseases
Endocrine & Metabolic Disorders
Other Diseases

Human Microbiome Market by Type

Market Overview
Bacterial Consortia Transplantation (BCT)/ Fecal Microbiotia Transplantation (FMT)
Live Biotherapeutic Product
Others

Human Microbiome Market by End User

Market Overview
Hospitals and Clinics
Long-Term Care Facilities
Other End Users

Human Microbiome Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Seres Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomebank (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle S.A. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seed Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Enterome (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pendulum (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quantbiome, Inc. (Dba Ombre) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vedanta Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Maat Pharma SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
International Flavors & Fragrances, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Optibiotx Health Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Synlogic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guangzhou Zhiyi Biotechnology Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aobiome (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siolta Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alveolus Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MRM Health NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biome Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanzyme Biologics (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomx (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nubiyota (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quorum Innovations (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

ヒトマイクロバイオームの世界市場規模、シェア、成長分析：製品別、疾患別、タイプ別、エンドユーザー別、地域別 - 産業予測（2024年～2031年）

Human Microbiome Market Size, Share, Growth Analysis, By Product (Drugs, Probiotics), By Disease (Infectious Dieases, Gastrointestinal Diseases), By Type, By End User, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

ヒトマイクロバイオーム市場：製品別

ヒトマイクロバイオーム市場：疾患別

ヒトマイクロバイオーム市場：タイプ別

ヒトマイクロバイオーム市場：エンドユーザー別

ヒトマイクロバイオーム市場：地域別